Relevant bibliographies by topics / KDIGO recommendations

Contents

  1. Journal articles
  2. Books

Academic literature on the topic 'KDIGO recommendations'

Author: Grafiati
Published: 5 June 2025
Last updated: 15 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'KDIGO recommendations.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "KDIGO recommendations"

1

Jifei, Guo, and Xi Yinliang. "KDIGO 2021 Blood Pressure Target Update and Chronic Kidney Disease Progression." Sriwijaya Journal of Internal Medicine 1, no. 2 (2023): 47–52. http://dx.doi.org/10.59345/sjim.v1i2.78.

Full text
Abstract:
In 2021, Kidney Disease: Improving Global Outcomes (KDIGO) published revised guidelines, including updated recommendations for the management of chronic renal disease and the control of blood pressure. The 2021 KDIGO Guidelines utilize current research and comprehensive scientific evidence to provide the most favorable blood pressure goals for those suffering from chronic kidney disease. The primary objective is to decelerate the advancement of renal impairment, mitigate problems linked to chronic kidney disease, and enhance the patient's quality of life. The 2021 KDIGO guidelines ground the b
APA, Harvard, Vancouver, ISO, and other styles
2

Karagiannis, Thomas, Apostolos Tsapas, and Eleni Bekiari. "KDIGO made 12 recommendations for managing diabetes with CKD." Annals of Internal Medicine 174, no. 3 (2021): JC26. http://dx.doi.org/10.7326/acpj202103160-026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jones, Graham RD. "eGFR – 10 years on from the KDIGO Global Recommendations." Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine 01, no. 02 (2022): 76–80. https://doi.org/10.62772/apfcb-news.2022.2.2.

Full text
Abstract:
In 2012, the key international kidney guideline group KDIGO (Kidney Disease - Improving Global Outcomes), released the document “Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD)”. It is not an understatement to say this this guideline changed the world of renal practice and the role of the routine laboratory in this field.
APA, Harvard, Vancouver, ISO, and other styles
4

Rojas-Rivera, Jorge Enrique, Sol Carriazo, and Alberto Ortiz. "Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal." Clinical Kidney Journal 12, no. 5 (2019): 629–38. http://dx.doi.org/10.1093/ckj/sfz127.

Full text
Abstract:
Abstract The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis shed light on the complex world of glomerulonephritis therapy. However, they may no longer apply to idiopathic membranous nephropathy, as recently concluded by the KDIGO 2019 Working Group. This is due to the discovery of autoantibodies such as anti-phospholipase A2 receptor (anti-PLA2R) that allow disease monitoring as well as to results from recent clinical trials, comparative cohort studies and meta-analyses. Perhaps the most disruptive of them is the Membranous Nephropath
APA, Harvard, Vancouver, ISO, and other styles
5

Saloua, abbassi, rouhi Salma, amrani Salma, chellak Saliha, and Boukhira Abderrahman. "Biological profile of secondary hyperparathyroidism in chronic renal failure." GSC Biological and Pharmaceutical Sciences 10, no. 3 (2022): 013–18. https://doi.org/10.5281/zenodo.6400420.

Full text
Abstract:
<strong>Introduction</strong>: Secondary hyperparathyroidism (SHPT) is a frequent complication of chronic renal failure and is associated with high morbidity and mortality. Our goal is to study the average time of development of SHPT, and the biological profile in accordance with recommended standards. <strong>Patients and methods</strong>: Retrospective descriptive study, including 134 chronically hemo-dialysed patients. Demographic, clinical, phosphocalcic and therapeutic data were analyzed. The phosphocalcic parameters were defined by KDOQI 2003 and KDIGO 2009 recommendations. <strong>Resul
APA, Harvard, Vancouver, ISO, and other styles
6

Saloua, abbassi, rouhi Salma, amrani Salma, chellak Saliha, and Boukhira Abderrahman. "Biological profile of secondary hyperparathyroidism in chronic renal failure." GSC Advanced Research and Reviews 10, no. 3 (2022): 013–18. https://doi.org/10.5281/zenodo.6401031.

Full text
Abstract:
<strong>Introduction</strong>: Secondary hyperparathyroidism (SHPT) is a frequent complication of chronic renal failure and is associated with high morbidity and mortality. Our goal is to study the average time of development of SHPT, and the biological profile in accordance with recommended standards. <strong>Patients and methods</strong>: Retrospective descriptive study, including 134 chronically hemo-dialysed patients. Demographic, clinical, phosphocalcic and therapeutic data were analyzed. The phosphocalcic parameters were defined by KDOQI 2003 and KDIGO 2009 recommendations. <strong>Resul
APA, Harvard, Vancouver, ISO, and other styles
7

Subbiah, Arunkumar, and Dipankar Bhowmik. "KDIGO recommendations on blood pressure management in chronic kidney disease." Kidney International 101, no. 6 (2022): 1299. http://dx.doi.org/10.1016/j.kint.2022.02.036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lam, Ngan N., Christine Dipchand, Marie-Chantal Fortin, et al. "Canadian Society of Transplantation and Canadian Society of Nephrology Commentary on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors." Canadian Journal of Kidney Health and Disease 7 (January 2020): 205435812091845. http://dx.doi.org/10.1177/2054358120918457.

Full text
Abstract:
Purpose of review: To review an international guideline on the evaluation and care of living kidney donors and provide a commentary on the applicability of the recommendations to the Canadian donor population. Sources of information: We reviewed the 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors and compared this guideline to the Canadian 2014 Kidney Paired Donation (KPD) Protocol for Participating Donors. Methods: A working group was formed consisting of members from the Canadian Society of Transplantation
APA, Harvard, Vancouver, ISO, and other styles
9

Saloua abbassi, Salma rouhi, Salma amrani, Saliha chellak, and Abderrahman Boukhira. "Biological profile of secondary hyperparathyroidism in chronic renal failure." GSC Advanced Research and Reviews 10, no. 3 (2022): 013–18. http://dx.doi.org/10.30574/gscarr.2022.10.3.0061.

Full text
Abstract:
Introduction: Secondary hyperparathyroidism (SHPT) is a frequent complication of chronic renal failure and is associated with high morbidity and mortality. Our goal is to study the average time of development of SHPT, and the biological profile in accordance with recommended standards. Patients and methods: Retrospective descriptive study, including 134 chronically hemo-dialysed patients. Demographic, clinical, phosphocalcic and therapeutic data were analyzed. The phosphocalcic parameters were defined by KDOQI 2003 and KDIGO 2009 recommendations. Results: The average time to onset of SHPT is 3
APA, Harvard, Vancouver, ISO, and other styles
10

Editorial, Article. "KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis. Translated into Russian by E.V. Zakharova." Nephrology and Dialysis 26, no. 2 (2024): 3–69. http://dx.doi.org/10.28996/2618-9801-2024-2suppl-3-69.

Full text
Abstract:
The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Management of Lupus Nephritis represents a focused update of the Lupus nephritis chapter from the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The aim is to assist clinicians caring for individuals with lupus nephritis. The update takes into consideration evidence from randomized controlled trials published since February 2022. As in 2021, the chapter follows the same template, providing guidance related to diagnosis, treatment, and special situations. Based on th
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "KDIGO recommendations"

1

Niaudet, Patrick, and Alain Meyrier. Minimal change disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0056_update_001.

Full text
Abstract:
Minimal change disease is characteristically responsive to high-dose corticosteroids. As this is the most common cause of nephrotic syndrome in children, and responses are usually prompt, response to 60 mg/m2/day of oral prednisolone (max. 80 mg) is often used as a diagnostic test. Adults respond more slowly and have a wider differential diagnosis, and often a high risk of side effects, so therapy is not recommended without confirmation by renal biopsy. Then first-line treatment is again prednisolone or prednisone, at 1 mg/kg/day (max. 60 mg). KDIGO and other treatment protocols recommend 6 we
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'KDIGO recommendations' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography